Organon (OGN) Cash & Equivalents (2020 - 2026)

Organon has reported Cash & Equivalents for 7 years, with the latest figure at $1.1 billion in Q2 2026.

• Cash & Equivalents for Q2 2026 came in at $1.1 billion, up 88.98% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.1 billion (up 88.98% YoY), and the FY2025 annual result was $574.0 million, down 14.96% from the prior year.
• Cash & Equivalents advanced to $1.1 billion in Q2 2026, from $1.1 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $1.1 billion in Q2 2026 and troughed at $326.0 million in Q2 2023.
• A 5-year average of $649.6 million and a median of $635.5 million in 2025 frame the typical range for Cash & Equivalents.
• The largest YoY upside for Cash & Equivalents was 392.2% in 2022 against a maximum downside of 50.5% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $706.0 million in 2022, then declined by 1.84% to $693.0 million in 2023, then slipped by 2.6% to $675.0 million in 2024, then retreated by 14.96% to $574.0 million in 2025, then soared by 97.21% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $1.1 billion in Q2 2026, $1.1 billion in Q1 2026, and $574.0 million in Q4 2025.